AI Levodopa Timing Improved UPDRS 4.4 Points in 5 Parkinson Patients
A 2026 open-label feasibility trial involving 5 Parkinson’s disease patients found that app-randomized levodopa timing was associated with a mean 4.4-point improvement on the Unified Parkinson’s Disease Rating Scale, but the signal missed conventional statistical significance at p = 0.063.1 The narrow conclusion is feasibility: this was a dosing experiment that justified a blinded controlled …
